Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $3,294,623.88 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Brett Monia sold 44,034 shares of the firm’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $74.82, for a total transaction of $3,294,623.88. Following the sale, the chief executive officer owned 224,683 shares in the company, valued at approximately $16,810,782.06. The trade was a 16.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ionis Pharmaceuticals Stock Up 1.6%

Ionis Pharmaceuticals stock traded up $1.20 during mid-day trading on Tuesday, reaching $77.53. The company’s stock had a trading volume of 4,894,343 shares, compared to its average volume of 1,492,706. The business’s 50 day simple moving average is $78.90 and its 200 day simple moving average is $64.33. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $86.15. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. The company has a market capitalization of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The firm had revenue of $156.72 million during the quarter, compared to analysts’ expectations of $131.75 million. During the same quarter last year, the company posted ($0.95) earnings per share. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

IONS has been the topic of a number of analyst reports. Piper Sandler increased their price objective on shares of Ionis Pharmaceuticals from $70.00 to $77.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Wells Fargo & Company boosted their target price on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Oppenheimer boosted their target price on shares of Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Stifel Nicolaus raised their price objective on Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research report on Monday, October 6th. Finally, Wall Street Zen cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.05.

More Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several large investors have recently modified their holdings of the business. Steigerwald Gordon & Koch Inc. purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $25,000. Golden State Wealth Management LLC raised its position in shares of Ionis Pharmaceuticals by 198.4% during the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after buying an additional 250 shares in the last quarter. Mather Group LLC. bought a new stake in Ionis Pharmaceuticals during the third quarter worth about $27,000. Allworth Financial LP grew its position in Ionis Pharmaceuticals by 231.8% during the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after acquiring an additional 517 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.